Skip to main content
SpringerLink
Log in

Pediatric osteosarcoma: Treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP)— Advantages, disadvantages, and controversial issues

  • Chapter
Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies

Part of the book series: Cancer Treatment and Research ((CTAR,volume 62))

Abstract

This communication will review therapeutic and toxic effects of intraarterial cis-diamminedichloroplatinum-II (CDP) in the treatment of the primary tumor and will discuss controversial issues [1,2,3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results and prognostic factors derived from a 10-year experience. J Clin Oncol 8:1988–1997, 1990.

    PubMed  CAS  Google Scholar 

  2. Rosen G. The current management of malignant bone tumors: Where do we go from here? Med J Austral 148:373–377, 1988.

    PubMed  CAS  Google Scholar 

  3. Winkler K, Bielack S. Chemotherapy of osteosarcoma. Semin Orthop 3:48–58, 1988.

    Google Scholar 

  4. Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma, intra-arterial treatment of the primary tumor with cis-diamminedichloroplatinum-II (CDP). Angiographic, pathologic and pharmacologic studies. Cancer 51:402–407, 1983.

    Article  PubMed  CAS  Google Scholar 

  5. Jaffe N, Raymond AK, Ayala A et al. Effect of cumulative courses of intra-arterial cis-diamminedichloroplatinum-II on the primary tumor in osteosarcoma. Cancer 63:63–67, 1989.

    Article  PubMed  CAS  Google Scholar 

  6. Chuang VP, Benjamin RS, Jaffe N, et al. Radiographic and angiographic changes in osteosarcoma after intra-arterial chemotherapy. Am J Roentgenol 239:1065–1069, 1982.

    Article  Google Scholar 

  7. Shirkoda A, Jaffe N, Wallace S, et al. Computed tomography of osteosarcoma following intra-arterial chemotherapy. Am J Roentgenol 144:95–99, 1985.

    Article  Google Scholar 

  8. Pan G, Raymond AK, Carrasco CH, et al. Osteosarcoma: MR imaging after preoperative chemotherapy. Radiology —:517–526, 1990.

    Google Scholar 

  9. Jaffe N, Spears R, Eftekhari F, et al. Pathologic fracture in osteosarcoma. Impact of chemotherapy on primary tumor and survival. Cancer 59:701–709, 1987.

    Article  PubMed  CAS  Google Scholar 

  10. Jaffe N, et al. Intra-arterial cis-diamminedichloroplatinum-II in the management of Stage II B osteosarcoma in the pediatric and adolescent age group. Clinical Orthop Rel Res, 1991.

    Google Scholar 

  11. Kletzel M, Jaffe N. Systemic hypertension. A complication of intra-arterial cis-diamminedichloroplatinum-II infusion. Cancer 47:245–247, 1981.

    Article  PubMed  CAS  Google Scholar 

  12. Jaffe N, et al. Renal toxicity with cumulative doses of cis-diamminedichloroplatinum-II in pediatric patients with osteosarcoma: effect on creatinine clearance and methotrexate excretion. Cancer 59:1577–1581, 1987.

    Article  PubMed  CAS  Google Scholar 

  13. Ruiz L, et al. Auditory function in pediatric osteosarcoma patients treated with multiple courses of cis-diamminedichloroplatinum-II (CDP). Cancer Res 49:742–744, 1989.

    PubMed  CAS  Google Scholar 

  14. Wright KC, et al. Pulsed arterial infusions. Chemotherapeutic complications. Cancer 57:1952–1956, 1986.

    Article  PubMed  CAS  Google Scholar 

  15. Rosen G, Nitenberg A, Caparros B, et al. Cis-platinum in metastatic osteogenic sarcoma. In: Cis-platin: Current Status and New Developments. Prestayko AW, Crooke ST, Carter SK, Eds. Academic Press, New York, 1980, pp 465–475.

    Google Scholar 

  16. Pratt CB, Hayes A, Green AA, et al. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. Cancer Treat Rep 65:1021–1026, 1981.

    PubMed  CAS  Google Scholar 

  17. Sarna G, Skinner DG, Smith RB, et al. Cis-diamminedichloroplatinum (II) alone and in combination in the treatment of testicular and other malignancies. Cancer Treat Rep 64:1077–1082, 1980.

    PubMed  CAS  Google Scholar 

  18. Ochs JL, Freeman AI, Douglass HO, Jr., et al. Cis-dichlorodiammine-platinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62:239–245, 1978.

    PubMed  CAS  Google Scholar 

  19. Freeman AI, Ettinger LJ, Brecher ML. cis-dichlorodiammine-platinum II in childhood cancer. Cancer Treat Rep 63:1615–1620, 1979.

    PubMed  CAS  Google Scholar 

  20. Baum ES, Gaynon P, Greenburg L, et al. Phase II trials of cisplatin in refractory childhood cancer: children’s cancer study group report. Cancer Treat Rep 65:815–822, 1981.

    PubMed  CAS  Google Scholar 

  21. Nitschke R, Fagundo R, Berry DH, Falletta JM. Weekly administration of cis-dichloro-diammineplatinum (II) in childhood solid tumors. A Southwest Oncology Group study. Cancer Treat Rep 63:497–499, 1979.

    PubMed  CAS  Google Scholar 

  22. Gasparini M, Rouesse J, van Ooster A, et al. Phase II study of cis-platin in advanced osteogenic sarcoma. Cancer Treat Rep 69:211–213, 1985.

    PubMed  CAS  Google Scholar 

  23. Powers BE, Withrow SJ, Thrall DE, et al. Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer 67:126–134, 1991.

    Article  PubMed  CAS  Google Scholar 

  24. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma. Results of a cooperative German/Austrian study. J Clin Oncol 2:617–624, 1984.

    PubMed  CAS  Google Scholar 

  25. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma. Results of a randomized cooperative trial (COSS-82) with salvage. Chemotherapy based on histological tumor response. J Clin Oncol 6:329–337, 1988.

    PubMed  CAS  Google Scholar 

  26. Winkler K, Bielack S, Delling G, et al. Effect of intra-arterial versus intravenous cisplatin in addition to systemic doxorubicin high dose methotrexate and ifosfamide on histologic tumor response in osteosarcoma. Cancer 66:1703–1710, 1990.

    Article  PubMed  CAS  Google Scholar 

  27. Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high dose methotrexate, cisplatinum and doxorubicin for management of patients with nonmetastatic osteosarcoma. Cancer Treat Rep 70:1431–1432, 1986.

    PubMed  CAS  Google Scholar 

  28. Benjamin RS, Chawla SP, Murray J, et al. Preoperative chemotherapy for osteosarcoma: a treatment approach facilitating limb salvage with major prognostic indications. In: Adjuvant Therapy of Cancer IV. Jones SF, Salmon SE, Eds. Grune and Stratton, Philadelphia, 1984, pp 601–610.

    Google Scholar 

  29. Picci P, Bacci G, Compana R, et al. Neoadjuvant chemotherapy for osteosarcoma. Results of a prospective study. In: Recent Concepts in Sarcoma Treatment. Ryan JR, Baker LO, Eds. Kluwer Academic Publishers, Boston, 1987, pp 291–295.

    Google Scholar 

  30. Stine KC, Hockenberry MJ, Horrelson J, et al. Systemic doxorubicin and intra-arterial cisplatin preoperative chemotherapy plus post-operative adjuvant chemotherapy in patients with osteosarcoma. Cancer 63:848–853, 1989.

    Article  PubMed  CAS  Google Scholar 

  31. Graham-Pole J, Saleh R, Springfield D, et al. Neoadjuvant chemotherapy for limb osteosarcoma. In: Neoadjuvant Chemotherapy, Vol 169. Jacqultat CL, Weil M, Khayat D, Eds. John Libbey Eurotext, 1988, pp 615–520.

    Google Scholar 

  32. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498–504, 1984.

    PubMed  CAS  Google Scholar 

  33. Bielack S, Erttman R, Looft G, et al. Platinum disposition after intra-arterial and intravenous infusions of cisplatinum for osteosarcoma. Cancer Chemother Pharmacol 24:376–380, 1989.

    Article  PubMed  CAS  Google Scholar 

  34. Campbell TN, et al. Clinical pharmacokinetics of intra-arterial cisplatin in humans. J Clin Oncol 1:755–762, 1983.

    PubMed  CAS  Google Scholar 

  35. Oldfield EH, Clark WC, Dedrick RL, et al. Reduced systemic drug exposure by combining intra-arterial cis-diamminedichloroplatinum (II) with hemodialysis of regional venous drainage. Cancer Res 47:1962–1967, 1987.

    PubMed  CAS  Google Scholar 

  36. Stewart DJ, Benjamin RS, Zimmerman S, et al. Clinical pharmacology of intra-arterial cis-diamminedichloroplatinum (II). Cancer Res 43:917–920, 1983.

    PubMed  CAS  Google Scholar 

  37. Jaffe N, Frei E III, Traggis D, Watts, H. Weekly high dose methotrexate citrovorum factor in osteogenic sarcoma: presurgical treatment of primary tumor and of overt pulmonary metastases. Cancer 39:45–50, 1977.

    Article  PubMed  CAS  Google Scholar 

  38. Jaffe N, Raymond K, Ayala A, et al. Analysis of the efficacy of intra-arterial cis-diamminedichloroplatinum-II and high dose methotrexate with citrovorum factor rescue in the treatment of primary osteosarcoma. Res Cancer Treat 2:157–163, 1989.

    Google Scholar 

  39. Link MP, Goorin MA, Miser AW, et al. The effect of adjuvant chemotherapy on relaspe-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600–1606, 1986.

    Article  PubMed  CAS  Google Scholar 

  40. Rosen G. Neoadjuvant chemotherapy for osteogenic sarcoma. A model for the treatment of other highly malignant neoplasms. Rec Res Cancer Res 103:148–157, 1986.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, MD Anderson Cancer Center and University of Texas, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Norman Jaffe

Authors
  1. Norman Jaffe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical College of Ohio at Toledo, USA

    G. Bennett Humphrey

  2. University of Groningen, Netherlands

    H. Schraffordt Koops , W. M. Molenaar  & A. Postma ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Jaffe, N. (1993). Pediatric osteosarcoma: Treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP)— Advantages, disadvantages, and controversial issues. In: Humphrey, G.B., Koops, H.S., Molenaar, W.M., Postma, A. (eds) Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Cancer Treatment and Research, vol 62. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3518-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3518-8_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6561-7

  • Online ISBN: 978-1-4615-3518-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation